<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838223</url>
  </required_header>
  <id_info>
    <org_study_id>00000319</org_study_id>
    <nct_id>NCT04838223</nct_id>
  </id_info>
  <brief_title>Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA)</brief_title>
  <acronym>NASA</acronym>
  <official_title>Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coopervision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to measure how common nerve abnormalities are within a group of&#xD;
      patients who feel discomfort within their eyes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 2, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the prevalence of neuropathic corneal pain in patients with ocular surface discomfort.</measure>
    <time_frame>Day 1</time_frame>
    <description>As measured by the percent of subjects who report increased ocular surface discomfort upon challenge with hyperosmolar saline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the overlap of neuropathic corneal pain with dry eye disease in patients in diseases that are currently thought to be mutually exclusive.</measure>
    <time_frame>Day 1</time_frame>
    <description>As measured by the percent of subjects who report ocular surface discomfort, and either do or do not exhibit signs of dry eye disease as defined by Tear Break Up Time, Schirmer's test, and staining, and have an increase in Visual Analog Scale score of more than 2 steps upon instillation of hypertonic saline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish the prevalence of subtypes of patients with neuropathic corneal pain or with a neuropathic component of dry eye in patients with ocular surface discomfort.</measure>
    <time_frame>Day 1</time_frame>
    <description>As measured by the percent of subjects who report ocular surface discomfort, and have a decrease, partial decrease, or no change in Visual Analog Score score upon instillation of proparacaine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the overlap of neuropathic corneal pain and contact lens discomfort.</measure>
    <time_frame>1 study visit</time_frame>
    <description>Percent of contact lens wearers who report discomfort when wearing their contact lenses, and either do or do not exhibit signs of dry eye disease as defined by TBUT, Schirmer's test, and staining, and have an increase in VAS score of more than 2 steps upon instillation of hypertonic saline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish the prevalence of anxiety/depression in patients with neuropathic corneal pain patients.</measure>
    <time_frame>Day 1</time_frame>
    <description>Percent of subjects who report increased ocular surface discomfort upon challenge with hyperosmolar saline and a history of anxiety/depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess for differences in in vivo confocal microscopy measures between dry eye disease patients and neuropathic corneal pain patients.</measure>
    <time_frame>Day 1</time_frame>
    <description>As measured by dendritic cell density, nerve fiber density, and microneuroma density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess for subtypes of neuropathic corneal pain differences in in vivo confocal microscopy measures between dry eye disease patients and neuropathic corneal pain patients.</measure>
    <time_frame>Day 1</time_frame>
    <description>As measured by dendritic cell density, nerve fiber density, and microneuroma density</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Dry Eye</condition>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Neuropathic Corneal Pain with Ocular Surface Discomfort</arm_group_label>
    <description>Participants diagnosed with neuropathic corneal pain with ocular surface discomfort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuropathic Corneal Pain with Dry Eye Disease</arm_group_label>
    <description>Participants diagnosed with dry eye disease and neuropathic corneal pain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NCP or Dry Eye in patients with ocular surface discomfort</arm_group_label>
    <description>Participants diagnosed with neuropathic corneal pain or with a neuropathic component of dry eye in patients with ocular surface discomfort</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperosmolar Response</intervention_name>
    <description>A single drop of hypertonic sodium chloride solution at room temperature will be instilled in each eye and change in pain/other symptoms after up to 90 seconds of application (to account for any initial irritation symptoms) will be observed.</description>
    <arm_group_label>NCP or Dry Eye in patients with ocular surface discomfort</arm_group_label>
    <arm_group_label>Neuropathic Corneal Pain with Dry Eye Disease</arm_group_label>
    <arm_group_label>Neuropathic Corneal Pain with Ocular Surface Discomfort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Proparacaine Challenge Test</intervention_name>
    <description>A single drop of Proparacaine hydrochloride ophthalmic solution, (AlcaineÂ®, 0.5%) will be used on each eye respectively and any change in pain/other symptoms will be noted after 90 seconds (to account for initial discomfort from the preservative in Proparacaine solution).</description>
    <arm_group_label>NCP or Dry Eye in patients with ocular surface discomfort</arm_group_label>
    <arm_group_label>Neuropathic Corneal Pain with Dry Eye Disease</arm_group_label>
    <arm_group_label>Neuropathic Corneal Pain with Ocular Surface Discomfort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Optional; only for Contact Lens Wearers</intervention_name>
    <description>The CLDEQ-8 is a validated eight-item scaled questionnaire developed to reflect the overall opinion of soft contact lenses.</description>
    <arm_group_label>NCP or Dry Eye in patients with ocular surface discomfort</arm_group_label>
    <arm_group_label>Neuropathic Corneal Pain with Dry Eye Disease</arm_group_label>
    <arm_group_label>Neuropathic Corneal Pain with Ocular Surface Discomfort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ocular Pain Assessment Survey (OPAS)</intervention_name>
    <description>Twenty seven-item quantitative questionnaire designed to provide an assessment of the symptoms and quality of life effect of ocular pain [18]. The 27 items of the OPAS questionnaire are graded on a scale of 0 to 10, or 10 to 100, where 0 indicates none and 10 or 100 indicate maximum.</description>
    <arm_group_label>NCP or Dry Eye in patients with ocular surface discomfort</arm_group_label>
    <arm_group_label>Neuropathic Corneal Pain with Dry Eye Disease</arm_group_label>
    <arm_group_label>Neuropathic Corneal Pain with Ocular Surface Discomfort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Visual Analogue Questionnaire</intervention_name>
    <description>Symptoms of ocular comfort and dryness will be graded for each eye on a scale of 0-10, where 0=extremely uncomfortable, extremely dry and 10=excellent comfort, no dryness. An average rating will be provided for the morning, afternoon and evening.</description>
    <arm_group_label>NCP or Dry Eye in patients with ocular surface discomfort</arm_group_label>
    <arm_group_label>Neuropathic Corneal Pain with Dry Eye Disease</arm_group_label>
    <arm_group_label>Neuropathic Corneal Pain with Ocular Surface Discomfort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1,000 subjects will be enrolled for this study based on the above criteria:&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presents with ocular surface discomfort or for dry eye care&#xD;
&#xD;
          -  Best corrected visual acuity of 20/40 or better in each eye&#xD;
&#xD;
          -  Subject reported duration of symptoms of at least 3 months&#xD;
&#xD;
          -  100 subjects will be required to be habitual contact lens wearers as defined by use of&#xD;
             contact lenses at least 5 hours per day at least 5 days per week for the last year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of contact lenses on the day of the visit&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Irregular corneas (e.g., ectatic disease, transplantation, or corneal dystrophies)&#xD;
&#xD;
          -  Ocular surgery in the past 3 months&#xD;
&#xD;
          -  Ocular infection in the past 3 months&#xD;
&#xD;
          -  Active ocular allergies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedram Hamrah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Canyon City Eye Care</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Eyecare and the Eyewear Gallery Optometry</name>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <zip>93449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western University of Health Sciences</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91766</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Southeastern University College of Optometry</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute - University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois College of Optometry</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korb &amp; Associates</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary EyeCare Associates</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pepose Vision</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Eye Specialists</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkyVision Centers</name>
      <address>
        <city>Westlake</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Doctors of Lancaster</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania (Scheie Eye Institute Perelman)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wheatlyn EyeCare</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center (Hamilton Eye Institute)</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proxymetacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

